STARTVerso3: A randomized, double-blind, placebo-controlled Phase III trial of faldaprevir in combination with pegylated interferon alfa-2a and ribavirin in treatment-experienced patients with chronic hepatitis C genotype-1 infection - Jacobson, I; Asselah, T; Ferenci, P; Foster, G
Paper presented at: AASLD The Liver Meeting; November 1–5, 2013; Washington, DC